| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/29/2006 | WO2006069153A2 Vitamin d receptor modulators |
| 06/29/2006 | WO2006068992A1 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 06/29/2006 | WO2006068991A1 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 06/29/2006 | WO2006068910A1 Glp-1 analog fusion protein formulations |
| 06/29/2006 | WO2006068594A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
| 06/29/2006 | WO2006068326A1 Novel polypeptide and the use thereof |
| 06/29/2006 | WO2006068199A1 Metabolically stable 3-oxy-1,2,4-triazole derivatives |
| 06/29/2006 | WO2006068163A1 Bicyclic pyrrole derivatives |
| 06/29/2006 | WO2006068117A1 Preventive for nephropathy and food having the function imparted thereto |
| 06/29/2006 | WO2006068075A1 Peroxisome proliferator-activated recepotr ϝ ligand |
| 06/29/2006 | WO2006068041A1 Composition having effect of promoting the decomposition of body fat and food or food additive containing the same |
| 06/29/2006 | WO2006067985A1 Novel polyphenol glycoside derived from acerola |
| 06/29/2006 | WO2006067866A1 Proanthocyanidin-containing composition |
| 06/29/2006 | WO2006067864A1 Proanthocyanidin-containing composition |
| 06/29/2006 | WO2006067611A1 Methods of modulating the activities of alpha7 nicotinic acetylcholine receptor |
| 06/29/2006 | WO2006067532A1 G-protein coupled receptor agonists |
| 06/29/2006 | WO2006067531A1 G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| 06/29/2006 | WO2006067428A2 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands |
| 06/29/2006 | WO2006067086A1 New 3-phenylpropionic acid derivatives for the treatment of diabetes |
| 06/29/2006 | WO2006066852A1 Food supplement |
| 06/29/2006 | WO2006066779A1 Novel cyclohexane derivatives |
| 06/29/2006 | WO2006066694A1 Method for the production of oxazoles by condensing aromatic aldehydes with a-ketoximes to n-oxides and then reacting the same with activated acid derivatives |
| 06/29/2006 | WO2006066637A1 Use of cyclodextrin complexes containing lipoic acid |
| 06/29/2006 | WO2006066599A2 Mas related g protein coupled receptors as drug targets |
| 06/29/2006 | WO2006066512A1 Pyrimidinone compounds, their preparation and use thereof |
| 06/29/2006 | WO2006054298A3 Glycogen synthase kinase-3 inhibitors |
| 06/29/2006 | WO2006035157A3 Substituted n-(benzyl)phenylacetamide derivative compounds, preparation method thereof and uses of same as ppar ligands in the treatment of lipid and/or glucidic disorders |
| 06/29/2006 | WO2006006082A3 Multi-ring compounds for regulating gut motility, food intake, and weight gain |
| 06/29/2006 | WO2005115396A3 Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
| 06/29/2006 | WO2005107730A3 Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 06/29/2006 | WO2005082414A3 Concomitant drugs of a sulfonamide and another therapeutic agent |
| 06/29/2006 | US20060142397 Use of a pparalpha agonist and metormin for decreasing the serum triglycerides |
| 06/29/2006 | US20060142391 Ppargamma-activating pharmaceutical composition |
| 06/29/2006 | US20060142389 Pharmaceutically useful salts of carboxylic acid derivatives |
| 06/29/2006 | US20060142358 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 06/29/2006 | US20060142357 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 06/29/2006 | US20060142329 Substituted fused N-heteroaryl compounds such as imidazo[1,5a]- or [1,2s]pyridines, e.g., 3-[3-(Pyrrolylphenoxy-2-hydroxypropyl)aminoalkyl]imidazo[1,5-a]pyridine derivatives, especially HCl salts; treating obesity and type 2 diabetes |
| 06/29/2006 | US20060142328 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142327 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142309 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
| 06/29/2006 | US20060142290 Compositions for affecting weight loss |
| 06/29/2006 | US20060142289 Method of treating migraine headaches |
| 06/29/2006 | US20060142277 Substituted aralkyl derivatives |
| 06/29/2006 | US20060142266 Compounds and their uses |
| 06/29/2006 | US20060142262 4-[1-(4-Methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester, for example, as antidiabetic and antiobesity agents |
| 06/29/2006 | US20060142258 Estrogen replacement therapy |
| 06/29/2006 | US20060142255 Hypocholesteremic preparations containing phytostenolesters of conjugated fatty acids, and methods of reducing serum cholesterol levels using the same |
| 06/29/2006 | US20060142209 Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| 06/29/2006 | US20060142206 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 06/29/2006 | US20060142200 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
| 06/29/2006 | US20060142185 Use of lupin conglutin for the treatment of type II diabetes |
| 06/29/2006 | US20060141599 Crystals of Glucokinase and methods of growing them |
| 06/29/2006 | US20060141580 Encoding protein with immunomodulatory activity, antiviral activity, and antitumor activity; treating any Type 1 interferon treatable disease including cancer; determining if a patient will respond to interferon treatment; transgenic animals |
| 06/29/2006 | US20060141128 Process for producing coated preparation |
| 06/29/2006 | US20060141079 Supplement foods and pharmaceuticals |
| 06/29/2006 | US20060140954 Novel human protein kinases and protein kinase-like enzymes |
| 06/29/2006 | US20060140945 Nephropathy-associated gene |
| 06/29/2006 | US20060140937 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 06/29/2006 | US20060140925 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use |
| 06/29/2006 | DE102004060041A1 Use of substituted cyclopropane acid derivative having dopamine receptor ligand activity to e.g. treat metabolic syndrome; reduce lipid in the plasma; lower free fatty acid in the plasma; and treat diabetic dyslipidemia |
| 06/29/2006 | DE10038110B4 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 06/29/2006 | CA2592236A1 Nutritional supplement |
| 06/29/2006 | CA2592201A1 Neuromedin s and the use thereof |
| 06/29/2006 | CA2592158A1 Methods of modulating the activities of alpha7 nicotinic acetylcholine receptor |
| 06/29/2006 | CA2591922A1 G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| 06/29/2006 | CA2590912A1 Bicyclic pyrrole derivatives |
| 06/29/2006 | CA2590494A1 Method for the production of oxazoles by condensing aromatic aldehydes with a-ketoximes to n-oxides and then reacting the same with activated acid derivatives |
| 06/29/2006 | CA2589988A1 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
| 06/29/2006 | CA2589664A1 Vitamin d receptor modulators |
| 06/29/2006 | CA2589647A1 Glp-1 analog fusion protein formulations |
| 06/28/2006 | EP1674575A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 06/28/2006 | EP1674456A2 Substituted alpha-halo-beta-keto-pyridinylpropanoates |
| 06/28/2006 | EP1674454A1 SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF |
| 06/28/2006 | EP1674452A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor |
| 06/28/2006 | EP1674109A1 Remedy for kidney diseases |
| 06/28/2006 | EP1674106A1 Dietetic composition |
| 06/28/2006 | EP1674100A1 Angiogenesis inhibitor |
| 06/28/2006 | EP1674099A1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 06/28/2006 | EP1674097A1 Compounds effecting glucokinase |
| 06/28/2006 | EP1674096A2 Hypoglycemics comprising organic zinc (II) complexes |
| 06/28/2006 | EP1674094A1 Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
| 06/28/2006 | EP1674092A1 Amino acid compositions |
| 06/28/2006 | EP1674090A1 Early insulin secretion promoter |
| 06/28/2006 | EP1674089A1 Accelerator for initial insulin secretion |
| 06/28/2006 | EP1673985A1 Functional sweetener |
| 06/28/2006 | EP1673376A2 Treating bone-related disorders with selective androgen receptor modulators |
| 06/28/2006 | EP1673353A1 Transition state structure and inhibitors of thymidine phosphorylases |
| 06/28/2006 | EP1673338A1 Fatty acid compounds, preparation and uses thereof |
| 06/28/2006 | EP1673098A1 Methods and means for modulating lipid metabolism |
| 06/28/2006 | EP1672988A1 Weight-loss supplement |
| 06/28/2006 | EP1558199A4 Therapeutic combination of carnitine and antioxidant polyphenols |
| 06/28/2006 | EP1401812B1 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| 06/28/2006 | EP1379258B1 Low salt forms of polyallylamine |
| 06/28/2006 | EP1355644B1 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 06/28/2006 | EP1268783B1 Antiangiogene Eigenschaften von Matin und Fragmenten oder Varianten davon |
| 06/28/2006 | EP1255561B1 Proteosome influenza vaccine |
| 06/28/2006 | EP1255536B1 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 06/28/2006 | EP1121372B1 Adenine derivatives |
| 06/28/2006 | CN1795180A Novel quinazoline derivatives and methods of treatment related to the use thereof |
| 06/28/2006 | CN1795163A Carboxylic compound and medicine comprising the same |